Bristol Myers Squibb Rewires Marketing Around AI to Speed Drug Information to Doctors
Bristol Myers Squibb is embedding AI into core marketing workflows to move faster while maintaining the scientific accuracy and regulatory compliance required in pharmaceuticals. The company is starting with a foundational change: redesigning how marketing briefs are created, a shift that affects every downstream campaign decision.
Anvita Karara, Vice President of Commercialization AI Strategy and Analytics at BMS, said the company is applying AI where it can improve outcomes across the full marketing cycle, not in isolated experiments. The goal is to help healthcare professionals access information more quickly, which ultimately benefits patients.
Three Operating Model Changes
BMS made three intentional shifts to scale AI across marketing teams:
- People: Upskilling teams to adopt AI in daily work rather than treating it as a separate capability.
- Processes: Making workflows more agile and insight-driven, with better cross-functional coordination.
- Technology: Embedding AI tools directly into existing systems so adoption happens naturally within current routines.
Why the Marketing Brief Matters
The marketing brief is where every campaign begins. When briefs vary across teams, brands, or regions, execution slows down and personalization becomes harder to scale.
By automating the heavy lifting in brief creation, marketers spend less time on administrative work and more time on strategy and creative decisions. This is particularly important in regulated industries where speed and consistency both matter.
For marketing professionals looking to understand how AI fits into enterprise-scale operations, AI for Marketing covers the strategic and tactical shifts required. Those managing marketing teams may also benefit from an AI Learning Path for Marketing Managers that addresses campaign optimization and workflow automation.
Your membership also unlocks:
